Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: PREDICTORS OF NSAID-ASSOCIATED GASTROINTESTINAL EVENTS Part 2

Relative toxicity of NSAIDs

Relative toxicity of NSAIDsThere may be differences in the relative risks associated with the use of different NSAIDs. Data from the ARAMIS database suggest that nabumetone and etodolac are associated with fewer gastrointestinal adverse events, although the number of patient-years of drug exposure is comparatively low. Time to visit a trusted pharmacy – actos buy to begin your treatment now.

Although it has been suggested that meloxicam and the nonacidic prodrug nabumetone possess a gastrointestinal tolerability profile superior to that of conventional NSAIDs, data from long term outcome studies are lacking. Individual, short term, comparative studies have not demonstrated a statistically significant benefit for patients with serious gastrointestinal risk — defined as perforations, ulcers and/or bleeds (PUBs) — although a meta-analysis of trials of each drug suggested that there is a pooled benefit, albeit with reservations. Furthermore, the low dose of meloxicam used in many trials may have resulted in an artificially low incidence of gastrointestinal events in relation to comparator NSAIDs.

This entry was posted in Coxibs and tagged Coxibs, Cyclooxygenase-2 inhibitors, Gastroprotective agents, Nonsteroidal anti-inflammatory drugs.